Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
54
MDP.TO Quote, Financials, Valuation and Earnings
Last price:
$2.66
Seasonality move
:
-5.78%
Day range:
$2.62 - $2.69
52-week range:
$1.96 - $5.56
Dividend yield:
0%
P/E ratio:
123.72x
P/S ratio:
0.53x
P/B ratio:
1.18x
Volume:
27.9K
Avg. volume:
49.9K
1-year change:
2.31%
Market cap:
$86.2M
Revenue:
$150.7M
EPS (TTM):
$0.02
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MDP.TO
Medexus Pharmaceuticals, Inc.
|
$35M | -$0.07 | -15.28% | 154.19% | $6.89 |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
-- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MDP.TO
Medexus Pharmaceuticals, Inc.
|
$2.66 | $6.89 | $86.2M | 123.72x | $0.00 | 0% | 0.53x |
|
COOL.CX
Core One Labs, Inc.
|
$0.15 | -- | $6.8M | -- | $0.00 | 0% | 32.71x |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
HEAL.CX
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
$0.05 | -- | $8.7M | -- | $0.00 | 0% | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
$0.0250 | -- | $256.9K | 0.65x | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MDP.TO
Medexus Pharmaceuticals, Inc.
|
28.67% | 0.127 | 34.77% | 0.29x |
|
COOL.CX
Core One Labs, Inc.
|
-- | 0.000 | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | 0.000 | -- | -- |
|
HEAL.CX
|
-- | 0.000 | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
40.99% | -3.518 | 19.05% | 2.85x |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-3.43% | 1.456 | 20.53% | 0.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MDP.TO
Medexus Pharmaceuticals, Inc.
|
$18.5M | $1.9M | 0.47% | 0.82% | 5.57% | $4M |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
-- | -$1.1M | -1117.27% | -- | -- | -$408.2K |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -$72.1K | -- | -- | -- | -$92.1K |
Medexus Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns MDP.TO or COOL.CX?
Core One Labs, Inc. has a net margin of -1.27% compared to Medexus Pharmaceuticals, Inc.'s net margin of --. Medexus Pharmaceuticals, Inc.'s return on equity of 0.82% beat Core One Labs, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MDP.TOMedexus Pharmaceuticals, Inc.54.32% -$0.01 $102.2M COOL.CXCore One Labs, Inc.-- -- -- -
What do Analysts Say About MDP.TO or COOL.CX?
Medexus Pharmaceuticals, Inc. has a consensus price target of $6.89, signalling upside risk potential of 152.26%. On the other hand Core One Labs, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Medexus Pharmaceuticals, Inc. has higher upside potential than Core One Labs, Inc., analysts believe Medexus Pharmaceuticals, Inc. is more attractive than Core One Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MDP.TOMedexus Pharmaceuticals, Inc.5 0 0 COOL.CXCore One Labs, Inc.0 0 0 -
Is MDP.TO or COOL.CX More Risky?
Medexus Pharmaceuticals, Inc. has a beta of 1.849, which suggesting that the stock is 84.947% more volatile than S&P 500. In comparison Core One Labs, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.458%.
-
Which is a Better Dividend Stock MDP.TO or COOL.CX?
Medexus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Core One Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medexus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Core One Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MDP.TO or COOL.CX?
Medexus Pharmaceuticals, Inc. quarterly revenues are $34.1M, which are larger than Core One Labs, Inc. quarterly revenues of --. Medexus Pharmaceuticals, Inc.'s net income of -$433.9K is higher than Core One Labs, Inc.'s net income of --. Notably, Medexus Pharmaceuticals, Inc.'s price-to-earnings ratio is 123.72x while Core One Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medexus Pharmaceuticals, Inc. is 0.53x versus 32.71x for Core One Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDP.TOMedexus Pharmaceuticals, Inc.0.53x 123.72x $34.1M -$433.9K COOL.CXCore One Labs, Inc.32.71x -- -- --
-
Which has Higher Returns MDP.TO or CURE.X.CX?
Biocure Technology has a net margin of -1.27% compared to Medexus Pharmaceuticals, Inc.'s net margin of --. Medexus Pharmaceuticals, Inc.'s return on equity of 0.82% beat Biocure Technology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MDP.TOMedexus Pharmaceuticals, Inc.54.32% -$0.01 $102.2M CURE.X.CXBiocure Technology-- -- -- -
What do Analysts Say About MDP.TO or CURE.X.CX?
Medexus Pharmaceuticals, Inc. has a consensus price target of $6.89, signalling upside risk potential of 152.26%. On the other hand Biocure Technology has an analysts' consensus of -- which suggests that it could fall by --. Given that Medexus Pharmaceuticals, Inc. has higher upside potential than Biocure Technology, analysts believe Medexus Pharmaceuticals, Inc. is more attractive than Biocure Technology.
Company Buy Ratings Hold Ratings Sell Ratings MDP.TOMedexus Pharmaceuticals, Inc.5 0 0 CURE.X.CXBiocure Technology0 0 0 -
Is MDP.TO or CURE.X.CX More Risky?
Medexus Pharmaceuticals, Inc. has a beta of 1.849, which suggesting that the stock is 84.947% more volatile than S&P 500. In comparison Biocure Technology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MDP.TO or CURE.X.CX?
Medexus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biocure Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medexus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Biocure Technology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MDP.TO or CURE.X.CX?
Medexus Pharmaceuticals, Inc. quarterly revenues are $34.1M, which are larger than Biocure Technology quarterly revenues of --. Medexus Pharmaceuticals, Inc.'s net income of -$433.9K is higher than Biocure Technology's net income of --. Notably, Medexus Pharmaceuticals, Inc.'s price-to-earnings ratio is 123.72x while Biocure Technology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medexus Pharmaceuticals, Inc. is 0.53x versus -- for Biocure Technology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDP.TOMedexus Pharmaceuticals, Inc.0.53x 123.72x $34.1M -$433.9K CURE.X.CXBiocure Technology-- -- -- --
-
Which has Higher Returns MDP.TO or HEAL.CX?
has a net margin of -1.27% compared to Medexus Pharmaceuticals, Inc.'s net margin of --. Medexus Pharmaceuticals, Inc.'s return on equity of 0.82% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MDP.TOMedexus Pharmaceuticals, Inc.54.32% -$0.01 $102.2M HEAL.CX-- -- -- -
What do Analysts Say About MDP.TO or HEAL.CX?
Medexus Pharmaceuticals, Inc. has a consensus price target of $6.89, signalling upside risk potential of 152.26%. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Medexus Pharmaceuticals, Inc. has higher upside potential than , analysts believe Medexus Pharmaceuticals, Inc. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings MDP.TOMedexus Pharmaceuticals, Inc.5 0 0 HEAL.CX0 0 0 -
Is MDP.TO or HEAL.CX More Risky?
Medexus Pharmaceuticals, Inc. has a beta of 1.849, which suggesting that the stock is 84.947% more volatile than S&P 500. In comparison has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MDP.TO or HEAL.CX?
Medexus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medexus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MDP.TO or HEAL.CX?
Medexus Pharmaceuticals, Inc. quarterly revenues are $34.1M, which are larger than quarterly revenues of --. Medexus Pharmaceuticals, Inc.'s net income of -$433.9K is higher than 's net income of --. Notably, Medexus Pharmaceuticals, Inc.'s price-to-earnings ratio is 123.72x while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medexus Pharmaceuticals, Inc. is 0.53x versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDP.TOMedexus Pharmaceuticals, Inc.0.53x 123.72x $34.1M -$433.9K HEAL.CX-- -- -- --
-
Which has Higher Returns MDP.TO or LOBE.CX?
Lobe Sciences Ltd. has a net margin of -1.27% compared to Medexus Pharmaceuticals, Inc.'s net margin of --. Medexus Pharmaceuticals, Inc.'s return on equity of 0.82% beat Lobe Sciences Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MDP.TOMedexus Pharmaceuticals, Inc.54.32% -$0.01 $102.2M LOBE.CXLobe Sciences Ltd.-- -$0.01 $5.9M -
What do Analysts Say About MDP.TO or LOBE.CX?
Medexus Pharmaceuticals, Inc. has a consensus price target of $6.89, signalling upside risk potential of 152.26%. On the other hand Lobe Sciences Ltd. has an analysts' consensus of -- which suggests that it could grow by 15780.37%. Given that Lobe Sciences Ltd. has higher upside potential than Medexus Pharmaceuticals, Inc., analysts believe Lobe Sciences Ltd. is more attractive than Medexus Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MDP.TOMedexus Pharmaceuticals, Inc.5 0 0 LOBE.CXLobe Sciences Ltd.0 0 0 -
Is MDP.TO or LOBE.CX More Risky?
Medexus Pharmaceuticals, Inc. has a beta of 1.849, which suggesting that the stock is 84.947% more volatile than S&P 500. In comparison Lobe Sciences Ltd. has a beta of 0.215, suggesting its less volatile than the S&P 500 by 78.507%.
-
Which is a Better Dividend Stock MDP.TO or LOBE.CX?
Medexus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lobe Sciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medexus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Lobe Sciences Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MDP.TO or LOBE.CX?
Medexus Pharmaceuticals, Inc. quarterly revenues are $34.1M, which are larger than Lobe Sciences Ltd. quarterly revenues of --. Medexus Pharmaceuticals, Inc.'s net income of -$433.9K is higher than Lobe Sciences Ltd.'s net income of -$1.1M. Notably, Medexus Pharmaceuticals, Inc.'s price-to-earnings ratio is 123.72x while Lobe Sciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medexus Pharmaceuticals, Inc. is 0.53x versus -- for Lobe Sciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDP.TOMedexus Pharmaceuticals, Inc.0.53x 123.72x $34.1M -$433.9K LOBE.CXLobe Sciences Ltd.-- -- -- -$1.1M
-
Which has Higher Returns MDP.TO or NSHS.CX?
NanoSphere Health Sciences, Inc. has a net margin of -1.27% compared to Medexus Pharmaceuticals, Inc.'s net margin of --. Medexus Pharmaceuticals, Inc.'s return on equity of 0.82% beat NanoSphere Health Sciences, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MDP.TOMedexus Pharmaceuticals, Inc.54.32% -$0.01 $102.2M NSHS.CXNanoSphere Health Sciences, Inc.-- -$0.00 -$1.8M -
What do Analysts Say About MDP.TO or NSHS.CX?
Medexus Pharmaceuticals, Inc. has a consensus price target of $6.89, signalling upside risk potential of 152.26%. On the other hand NanoSphere Health Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Medexus Pharmaceuticals, Inc. has higher upside potential than NanoSphere Health Sciences, Inc., analysts believe Medexus Pharmaceuticals, Inc. is more attractive than NanoSphere Health Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MDP.TOMedexus Pharmaceuticals, Inc.5 0 0 NSHS.CXNanoSphere Health Sciences, Inc.0 0 0 -
Is MDP.TO or NSHS.CX More Risky?
Medexus Pharmaceuticals, Inc. has a beta of 1.849, which suggesting that the stock is 84.947% more volatile than S&P 500. In comparison NanoSphere Health Sciences, Inc. has a beta of 0.627, suggesting its less volatile than the S&P 500 by 37.292%.
-
Which is a Better Dividend Stock MDP.TO or NSHS.CX?
Medexus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoSphere Health Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medexus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NanoSphere Health Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MDP.TO or NSHS.CX?
Medexus Pharmaceuticals, Inc. quarterly revenues are $34.1M, which are larger than NanoSphere Health Sciences, Inc. quarterly revenues of --. Medexus Pharmaceuticals, Inc.'s net income of -$433.9K is lower than NanoSphere Health Sciences, Inc.'s net income of -$13.1K. Notably, Medexus Pharmaceuticals, Inc.'s price-to-earnings ratio is 123.72x while NanoSphere Health Sciences, Inc.'s PE ratio is 0.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medexus Pharmaceuticals, Inc. is 0.53x versus -- for NanoSphere Health Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDP.TOMedexus Pharmaceuticals, Inc.0.53x 123.72x $34.1M -$433.9K NSHS.CXNanoSphere Health Sciences, Inc.-- 0.65x -- -$13.1K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 22
Lamb Weston Holdings, Inc. [LW] is down 2.59% over the past day.
Buy
54
BMRN alert for Dec 22
BioMarin Pharmaceutical, Inc. [BMRN] is down 3.03% over the past day.
Buy
82
RKLB alert for Dec 22
Rocket Lab Corp. [RKLB] is up 9.97% over the past day.
